Tamoxifen 10mg/tab 100 Tabletten by Magnus Pharmaceuticals

Usage

1. Determine your target protocol length based on cycle suppression depth before starting — have your full 100-tablet supply on hand so no phase is interrupted.
2. Begin at the induction dose (40mg/day, four tablets) on the appropriate start date for your cycle type, ensuring residual androgenic compounds are no longer actively suppressing HPG output.
3. Administer each daily dose as a whole-tablet multiple with a meal to support gastrointestinal comfort and consistent absorption; do not split tablets to achieve intermediate doses.
4. Step down to the next dose tier at the scheduled phase boundary — do not extend any phase beyond its planned duration without a clinical rationale based on monitored recovery markers.
5. At the weaning-off phase (10mg/day, one tablet), maintain this dose for at least one to two weeks before cessation; do not stop Tamoxifen abruptly after an extended protocol.
6. After completing the full taper, obtain post-PCT bloodwork (LH, FSH, total testosterone, estradiol) to confirm adequate recovery before discontinuing support and returning to baseline training.

Warnings

Frequently asked questions

What is the recommended Tamoxifen dosing structure for a standard PCT protocol?

A standard Tamoxifen PCT protocol uses a front-loaded, descending dose ladder: 40mg/day for weeks one and two, stepping down to 20mg/day for weeks three and four. More comprehensive programmes extend this with a 10mg/day weaning-off phase for one to two additional weeks. The Magnus Pharmaceuticals 10mg tablet makes each step in this ladder executable as an exact whole-tablet multiple — no splitting required at any phase.

Should Tamoxifen dose be tapered down gradually or stopped all at once at the end of PCT?

Gradual tapering is the preferred approach rather than abrupt cessation. Stopping a SERM suddenly after extended use can trigger estrogen-receptor up-regulation rebound as the antagonist is removed, potentially destabilising the hormonal environment that has been carefully restored. A structured step-down — for example, finishing at 10mg/day for one to two weeks — allows the pituitary to consolidate its recovered gonadotroph sensitivity before SERM support is fully withdrawn.

What factors determine how long a Tamoxifen PCT protocol should run?

Protocol length is governed by the degree of HPG-axis suppression, which reflects compound selection, cycle duration, and total AAS dose. Recovery velocity — tracked by rising LH, FSH, and testosterone levels — is the practical endpoint marker. Longer or more suppressive cycles typically require eight to ten weeks of SERM support; shorter exposures may resolve in four to six weeks. The 100-tablet pack is sized to cover the full upper range of this window without mid-protocol resupply.

Why is the 10mg tablet strength particularly useful for PCT protocol design compared to higher-dose tablets?

The 10mg denomination is the lowest unit strength in this product category, giving it a structural advantage for multi-step taper protocols. It allows practitioners to build a four-point descending dose ladder — 40, 30, 20, and 10mg/day — using only whole tablets at every stage. Higher-strength tablets require splitting to achieve the same granularity, introducing API content variability that undermines the dose precision a taper is designed to provide.

Are Magnus Pharmaceuticals Tamoxifen Citrate 10mg tablets suitable for splitting if a lower dose is needed?

While the tablets can be physically divided, splitting is unnecessary for standard PCT dose steps when using the 10mg denomination — all common dose points (10, 20, 30, 40mg) are achievable as whole-tablet multiples. Avoiding splitting also preserves the content uniformity guarantee that applies to the intact compressed tablet as released, since HPLC and uniformity testing is performed on whole units rather than halved fragments. (2) angle_used

Manufacturer

Formulation precision for oral solid-dose products at Magnus Pharmaceuticals is governed by a compound-specific development approach in which tablet mass, API load, and content uniformity targets are established independently for each active ingredient rather than applied from a generic compression template. For Tamoxifen Citrate at 10mg per tablet, the critical quality parameter is uniformity of API distribution across the tablet matrix: at this unit dose level, even minor granulation inconsistencies translate into clinically meaningful dose variation across individual tablets. Magnus Pharmaceuticals addresses this through a validated wet-granulation sequence with defined particle-size specification for the Tamoxifen Citrate API, followed by in-process sampling at compression to confirm blend homogeneity before full batch production proceeds. The finished-tablet lot is then subjected to a separate HPLC quantification step — independently executed from the incoming API intake test — that confirms the declared 10mg content against a certified Tamoxifen Citrate reference standard and documents tablet-to-tablet content uniformity data as part of the certificate of analysis issued with each released batch. This two-stage analytical architecture — intake testing and finished-product release testing operating as distinct, non-substitutable checkpoints — reflects Magnus Pharmaceuticals' formulation development philosophy: that dose reliability in a precision taper protocol is only as credible as the quality system that produces it.